News

PITTSBURGH, Sept. 29, 2016 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), a privately held, clinical stage pharmaceutical company focused on discovering and developing disease-modifying therapies for neurodegenerative diseases, announced today that, aided by a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), it will use its validated discovery platform to simultaneously discover drug …

Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease Read More »

Scale Angels investee company Cognition Therapeutics commences clinical trials in Melbourne Cognition Therapeutics Inc. (CogRx), a privately held pharmaceutical company focused on discovering and developing disease-modifying therapies for Alzheimer’s and related neurodegenerative diseases, announced today that it has commenced Phase 1 clinical studies in Melbourne. This study will examine the safety and pharmacokinetics of the …

Cognition Therapeutics Commences Clinical Trials in Melbourne Read More »

PITTSBURGH, Sept. 8, 2015 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), a privately held pharmaceutical company focused on discovering and developing disease-modifying therapies for Alzheimer’s and related neurodegenerative diseases, announced today that it has completed a Series B preferred stock financing totaling $12 million. Golden Seeds led the investment syndicate, which included, Bios Memory SPV1, Cowtown Angels, Scale Investors, Dolby Family Ventures, Maine …

Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing Read More »

PITTSBURGH, May 21, 2014 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, announced today that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer’s disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH …

NIH to Fund CogRx’s Strong Molecule Soluble Abeta Receptor Antagonist Program for Treatment of AD Read More »

PITTSBURGH, April 1, 2014 /PRNewswire/ –Patent describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer’s disease. CogRx has pioneered the use of disease-relevant screening technology that closely models the pathology of neurodegenerative diseases and novel, high-quality …

Cognition Therapeutics, Inc. (CogRx) receives a US Patent for a Drug to Fight Alzheimer’s Disease Read More »